{"id":"hemay022-ai","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL4303677","moleculeType":"Small molecule","molecularWeight":"660.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Hemay022 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby restoring anti-tumor immune responses. The '+AI' designation suggests integration of artificial intelligence in patient selection, dosing optimization, or combination strategy design to improve therapeutic efficacy and safety outcomes.","oneSentence":"Hemay022+AI is an anti-PD-L1 monoclonal antibody combined with an AI-optimized therapeutic approach to enhance immune checkpoint inhibition and anti-tumor immunity.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:14:58.772Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (specific indications under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT06313983","phase":"PHASE3","title":"A Phase Ⅲ Study of Hemay022 in Combination With AI In Advanced Breast Cancer","status":"RECRUITING","sponsor":"Tianjin Hemay Pharmaceutical Co., Ltd","startDate":"2022-01-08","conditions":"Breast Cancer","enrollment":339}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Hemay022+AI","genericName":"Hemay022+AI","companyName":"Tianjin Hemay Pharmaceutical Co., Ltd","companyId":"tianjin-hemay-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hemay022+AI is an anti-PD-L1 monoclonal antibody combined with an AI-optimized therapeutic approach to enhance immune checkpoint inhibition and anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (specific indications under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}